Diagnostic and Interventional Cardiology

$Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) #ACC20/#WCCardio$

News | Heart Failure

Vericiguat Improves Outcomes in Patients with Worsening Heart Failure

March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational ...

March 29, 2020

Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session. #ACC20 #ACC2020

Feature | Heart Valve Technology | Dave Fornell, Editor

TAVR Shows Favorable Safety in Patients with Bicuspid Valve

March 29, 2020 — Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve ...

March 29, 2020

POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020

News | Atrial Fibrillation

March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing ...

March 29, 2020

Sponsored Content

ASCEND provides the tools that not only address the unique needs of each cardiovascular subspecialty and to care for patients from infancy into their golden years, they also innovates next-generation solutions and services that empower the provider community to truly transform their cardiovascular services

Feature | Information Technology

SPONSORED CONTENT: Unveiling the Future of Cardiovascular Workflow

Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...

March 21, 2024

Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial. #ACC20 #ACC2020

News | Pharmaceuticals | Dave Fornell, Editor

Two-Dose a Year LDL-lowering Drug Had Significant Impact in Pooled Analysis of ORION Trials

March 28. 2020 — Among adults with heterozygous familial hypercholesterolemia, those who received the drug inclisiran ...

March 28, 2020

Find more news from ACC 2020.Women carry heavier burden of chest pain, but less artery narrowing according to data in a substudy of the ISCHEMIA Trial. #ACC20 #ACC2020 #ISCHEMIA

News | Womens Cardiovascular Health

Sex Differences in Stress Test and CCTA Findings and Symptoms in the Ischemia Trial

March 28, 2020 — Women with coronary artery disease that reduces blood flow and oxygen to the heart muscle (ischemia) ...

March 28, 2020

News | Heart Failure

Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis

March 28, 2020 — New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse ...

March 28, 2020

Sponsored Content

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability to diagnose cardiac disease with greater accuracy and precision

Feature | Cardiac Imaging

SPONSORED CONTENT: Finding the Right Solution

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...

March 05, 2024

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

News | Antiplatelet and Anticoagulation Therapies

Antiplatelet Genetic Testing Missed Goal to Cut Cardiovascular Events in Half

March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to ...

March 28, 2020

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20

News | Peripheral Artery Disease (PAD)

Rivaroxaban Reduces Risks in Peripheral Artery Disease Post-Intervention

March 28, 2020 — People with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with ...

March 28, 2020

News | Coronavirus (COVID-19)

ESC and Other Societies Creates a COVID-19 Resource Pages for Cardiology

March 27, 2020 — The European Society of Cardiology (ESC) has created a novel coronavirus resource page with information ...

March 27, 2020

Sponsored Content

Blog

BLOG: Combining Local Impedance with Contact Force to Perform RF Ablation

When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...

December 11, 2023

News | Coronavirus (COVID-19)

Italian Cardiologist Maurizio Galderisi Died From COVID-19

March 27, 2020 — In Italy today, novel coronavirus (COVID-19) claimed the life of well known cardiologist Maurizio ...

March 27, 2020

Videos | Coronavirus (COVID-19)

VIDEO: Telemedicine in Cardiology and Medical Imaging During COVID-19

Regina Druz, M.D., FASNC, a member of the American Society of Nuclear Cardiology (ASNC) Board of Directors, chairwomen ...

March 26, 2020

Videos | FFR Technologies

VIDEO: Use of FFR-CT to Non-invasively Evaluate Coronary Lesion Severity

James Udelson, M.D., chief of the division of cardiology, Tufts Medical Center, explains how cardiac computed tomography ...

March 26, 2020

Sponsored Content

Case Study | Hemodynamic Monitoring Systems

TECH BRIEF — Integrated Hemodynamic Monitoring System Helps Improve Lab Performance, Efficiency

Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...

November 14, 2023

The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.

News | Heart Valve Technology

First Human Use of Transcatheter Duo Tricuspid Valve Announced in Ireland

March 25, 2020 — CroiValve announced the successful first human use of its Duo Tricuspid Coaptation Valve technology for ...

March 25, 2020

News | Coronavirus (COVID-19) | Dave Fornell, Editor

FDA Takes Action to Increase Supply of Personal Protective Equipment Amid COVID-19 Shortages

March 25, 2020 — The U.S. Food and Drug Administration (FDA) said it is taking action to increase U.S. supplies of ...

March 25, 2020

Hydroxychloroquine causes prolonged QT intervals and cardiac arrhythmias, so this needs to be considered in patients being treated with this drug for COVID-19. #COVID19 #SARScov2 #coronavirus

Feature | Coronavirus (COVID-19) | Marianne Pop, Pharm.D, BCPS

COVID-19 Hydroxychloroquine Treatment Brings Prolonged QT Arrhythmia Issues

It has been more than three months since the word coronavirus was uttered on everyone’s lips and all over the social ...

March 24, 2020